Last month, we were contacted by Canada’s Drug Agency (CDA) for an upcoming Reimbursement Review of Dabrafenib-trametinib for BRAF V600E mutant anaplastic thyroid cancer that will be reviewed by the Formulary Management Expert Committee in March 2025. They are looking for assistance from TFC to locate a thyroid cancer patient with lived experience to present to the committee and have a dialogue with them, to help the committee better understand the day-to-day impacts of living with Thyroid Cancer and how they undergo treatment. This helps the committee make more informed recommendations during a reimbursement review.